ULORIC

This brand name is authorized in United States. It is also authorized in Canada.

Active ingredients

The drug ULORIC contains one active pharmaceutical ingredient (API):

1	Febuxostat UNII 101V0R1N2E - FEBUXOSTAT
	Uric acid is the end product of purine metabolism in humans and is generated in the cascade of hypoxanthine → xanthine → uric acid. Both steps in the above transformations are catalyzed by xanthine oxidase (XO). Febuxostat is a 2-arylthiazole derivative that achieves its therapeutic effect of decreasing serum uric acid by selectively inhibiting XO.
	Read more about Febuxostat

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
ULORIC Tablet	MPI, US: SPL/PLR	FDA, National Drug Code (US)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
M04AA03	Febuxostat	M Musculo-skeletal system → M04 Antigout preparations → M04A Antigout preparations → M04AA Preparations inhibiting uric acid production
Discover more medicines within M04AA03

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
CA	Health Products and Food Branch	02357380
US	FDA, National Drug Code	43353-305, 55154-5158, 55154-5159, 64764-677, 64764-918